ScientificApproach

Sadly, things aren't looking good for SB204. The first trial failed, the other showed merely minor improvements:

Info about phase 3: This is going to be a lengthy one: Estimated Enrollment: 1300 Study Start Date: February 2016 Estimated Study Completion Date: October 2017 Estimated Primary Completion Date: ...

Phase 2b successful: [Edited link out] Phase 3 covering 2600 patients planned for Q1 2016.

On 6/10/2013 at 9:58 PM, CBIOT13 said: Most consider the Phase III trial to be the definitive one though, because it has such a large sample size and the efficacy of the drug in comparison to...